[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"GFPC Investigation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100636247","observational-multicenter-study-in-patients-receiving-chemotherapy-and-amivantamab-for-metastatic-non-small-cell-lung-cancer-100636247",false,"NCT07563205","Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer","Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer as Part of an Early Access Program","OMAE","Inclusion Criteria:\n\n* Patient over 18 years old\n* Cohort A: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion treated with amivantamab-platimum based chemotherapy via an early access program in first line setting.\n* Cohort B: Patient with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 19 or 21 treated with amivantamab-platimum based chemotherapy post osimertinib (with or without chemotherapy) via an early access program.\n* Patient covered by the French National Health Insurance system or by an approved third-party payer\n* Patient who does not object to the collection of their personal data for research purposes (an information sheet will be provided to all living participants; for deceased participants, documented non-opposition in the medical record is not required)\n\nExclusion Criteria:\n\n* Patient placed under legal guardianship or subject to a protective legal measure\n* Patient who explicitly refuses the collection or use of their personal data for research purposes\n* Patient not enrolled, managed, or followed at the investigating site by a qualified site investigator","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to understand how well a treatment combining chemotherapy and amivantamab works in real life, and how safe it is, in adults with metastatic non-small cell lung cancer (NSCLC) who have certain EGFR gene mutations.\n\nThe study includes two groups of people:\n\n* Group A: people with an EGFR exon 20 insertion who receive amivantamab together with platinum-based chemotherapy as their first treatment, through an early access program.\n* Group B: people with an EGFR exon 19 or exon 21 mutation who receive amivantamab with platinum-based chemotherapy after having been treated with osimertinib (with or without chemotherapy), also through an early access program.\n\nThe main question the study wants to answer is:\n\nHow long can the combination of amivantamab and chemotherapy keep the cancer from coming back or getting worse in these two groups of people?\n\nPeople already receiving amivantamab and chemotherapy for NSCLC through an early access program may be included. They will continue to be followed by their usual oncologist as part of their normal medical care. The study will simply collect their medical information from March 21, 2024 to October 21, 2025.\n\nNo extra tests or procedures are required. This is an observational study, carried out by the GFPC and partner centers in France.",[25,26,27,28,29,30,31,32,33],"Non-Small Cell Lung Cancer","Non Small Cell Lung Cancer Metastatic","Non Small Cell Lung Cancer NSCLC","Non Small Cell Lung Carcinoma","NSCLC","EGFR","EGFR Exon 20 Insertion Mutation","EGFR Exon 19 Deletion Mutation","EGFR Exon 21 Mutation",[35,36,37,38,39,40,29],"Lung Cancer","Non Small Cell lung cancer","Metastatic lung cancer","EGFR Exon 20","EGFR Exon 19","EGFR Exon 21","RECRUITING","2026-04-24",{"date":44,"type":45},"2026-05-01","ACTUAL",{"date":47,"type":45},"2025-11-19",{"date":49,"type":21},"2027-11-19",{"name":51,"class":52},"GFPC Investigation","OTHER",16,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100611634","long-terms-responders-in-metastatic-lung-cancer-better-understanding-for-better-management-lungevity-study-100611634","NCT07243132","Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)","Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)","LUNGEVITY","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patients alive after more than three years from diagnosis with stage IV or Stage III NSCLC or SCLC, not treated with cytotoxic chemotherapy at the time of inclusion (the patient may be undergoing imunotherapy, targeted therapy or surveillance).\n* Patients covered by the French National Health Insurance program or with thirdparty-payer health insurance\n\nExclusion Criteria:\n\n* Difficulties for understanding French\n* Patients undergoing treatment with cytotoxic chemotherapy\n* Patients under legal guardianship, under curatorship or tutorship\n* Insufficient cognitive capacity to answer questions\n* Inability to obtain data collection (lost to follow-up, patient's refusal for data collection)\n* Patients refusing the collection of their data (an information sheet will be provided)",{"count":63,"type":21},1000,"The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment.\n\nParticipants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study.\n\nThey will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.",[66,67,68],"Metastatic Lung Cancer","Metastatic NSCLC","Metastatic Small Cell Lung Cancer",[70,71,67,72],"long-terms responders","Mestastatic Lung Cancer","Metastatic small cell lung cancer",{"date":74,"type":45},"2026-04-27",{"date":76,"type":45},"2025-07-02",{"date":78,"type":21},"2031-01-31",{"name":51,"class":52},46,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100565768","phase-4-prospective-master-protocol-for-evaluation-of-systemic-therapeutics-in-elderly-with-thoracic-malignancies-100565768","NCT06646471","PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies","PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly","PROMETHEE","Inclusion Criteria:\n\n* Patient ≥70 years\n* Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage\n* Patient naïve to systemic anticancer treatment for bronchial neoplasia\n* Patient covered by social security\n* Patient eligible for systemic treatment\n* Systemic treatment with marketing authorization in the indication, available in routine care early access or compassionate access.\n* Patient able to understand the protocol\n* Patient not opposed to the collection of data concerning him\u002Fher\n* Signature of study consent form.\n\nExclusion Criteria:\n\n* Patients under guardians or curators\n* Patient not under the care of the investigating center and not monitored by the investigating center\n* Patient already treated with systemic therapy for NSCLC","70 Years",{"count":91,"type":21},500,"INTERVENTIONAL",[94],"PHASE4","The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to:\n\n* characterize participants in terms of geriatrics, biology and carcinology\n* describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life.\n\nAt the same time, exploratory sub-cohorts will be identified including participants treated uniformly with the same molecule, and\u002For the same innovative strategy.\n\nParticipants will be followed in accordance with investigator's usual clinical practice at the corresponding site. They will be asked to:\n\n* visit the clinic as per physician's request for checkups and tests for assessing general condition and clinical efficacy and tolerance of current treatment.\n* perform the necessary regular para-clinical examinations (lab testing, imaging, re-biopsy).\n* provide blood samples for bio-bank repository\n* perform assessments specific to older adults\n* answer three quality of life questionnaires",[97,35],"Non Small Cell Lung Cancer",{"date":99,"type":45},"2026-04-29",{"date":101,"type":45},"2024-09-26",{"date":103,"type":21},"2028-08-31",{"name":51,"class":52},41,""]